Abstract:Cross‐species chimeric antibodies single‐chain fragment variable (scFv)‐CH2, scFv‐CH3, and scFv‐Fc, were generated by fusing avian‐derived scFv obtained by phage display technology with different sized Fc fragments of mouse‐derived IgG. CH2, CH3, and intact Fc demonstrated varying degrees of efficacy in prolonging the half‐life of scFv compared with unfused scFv in vivo. Chicken single‐chain fragment variable (IgY‐scFv) is a functional fragment and an emerging development in genetically engineered antibodies with a wide range of biomedical applications. However, scFvs have considerably shorter serum half‐life due to the absence of antibody Fc region compared with the full‐length antibody, and usually requires continuous intravenous administration for efficacy. A promising approach to overcome this limitation is to fuse scFv with immunoglobulin G (IgG) Fc region, for better recognition and mediation by the neonatal Fc receptor (FcRn) in the host. In this study, engineered mammalian ΔFc domains (CH2, CH3, and intact Fc region) were fused with anti‐canine parvovirus‐like particles avian IgY‐scFv to produce chimeric antibodies and expressed in the HEK293 cell expression system. The obtained scFv‐CH2, scFv‐CH3, and scFv‐Fc can bind with antigen specifically and dose‐dependently. Surface plasmon resonance investigation confirmed that scFv‐CH2, scFv‐CH3, and scFv‐Fc had different degrees of binding to FcRn, with scFv‐Fc showing the highest affinity. scFv‐Fc had a significantly longer half‐life in mice compared with the unfused scFv. The identified ΔFcs are promising for the development of engineered Fc‐based therapeutic antibodies and proteins with longer half‐lives. The avian IgY‐scFv‐mammalian IgG Fc region opens up new avenues for antibody engineering, and it is a novel strategy to enhance the rapid development and screening of functional antibodies in veterinary and human medicine.

Potential Use of Single-Chain Fv Proteins for Human and Animal Health

Chimerism of avian IgY‐scFv and truncated IgG‐Fc: A novel strategy in cross‐species antibody generation and enhancement

The Potential of Single-Chain Variable Fragment Antibody: Role in Future Therapeutic and Diagnostic Biologics

Generation of Chicken Antibody Libraries and Selection of Antigen Binders

[The Potential of Avian Cytokines As Immunotherapeutics and Vaccine Adjuvants].

Heavy chain-only antibodies with a stabilized human VH in transgenic chickens for therapeutic antibody discovery

Construction of a human scFv antibody library with VH regions randomized and its application

Neutralization Analysis of a Chicken Single-Chain Variable Fragment Derived from an Immune Antibody Library Against Infectious Bronchitis Virus

Single-chain fragment variable produced by phage display technology: Construction, selection, mutation, expression, and recent applications in food safety.

scFv Antibody: Principles and Clinical Application

A review on the application of chicken immunoglobulin Y in aquaculture

Human Hexa-Histidine-Tagged Single-Chain Variable Fragments for Bioimaging of Bacterial Infections

In Vivo Applications of Single Chain Fv (Variable Domain) (scFv) Fragments

Progress On Chicken Monoclonal Antibody Technology

Recombinant Scfv Inhibit Newcastle Disease Virus in Vitro Infection

Chicken egg yolk antibodies (IgY) as non-antibiotic production enhancers for use in swine production: a review

Advancement in the development of single chain antibodies using phage display technology

Construction and Characterization of a Highly Reactive Chicken-Derived Single-Chain Variable Fragment (scfv) Antibody Against Staphylococcus Aureus Developed with the T7 Phage Display System.

Screening scFv antibodies against infectious bursal disease virus by co-expression of antigen and antibody in the bacteria display system.

Human Antibody Production in Transgenic Animals

A compact phage display human scFv library for selection of antibodies to a wide variety of antigens